and private interests; and acts as the coordinator of the total refugee and entrant resettlement effort for ACF and the Department.

The Discretionary Grants Unit, responsible to the Office of the Director, provides technical administration of ORR discretionary grants; reviews, certifies and/or signs all discretionary grants; assures that all discretionary grants awarded by ORR conform with applicable statutes, regulations, and policies; prepares discretionary grant awards, ensures incorporation of necessary grant terms and conditions, and prepares reports and analyses on the grantee's use of funds; maintains liaison and coordination with appropriate ACF and HHS organizations to ensure consistency between ORR discretionary grant systems and the Department's grant payment systems; and performs audit resolution activities for ORR discretionary grant program.

B. Delete KR.20 Functions, Paragraph C, in its entirety and replace with the following.

C. Division of Community Resettlement directs and manages effective refugee resettlement through the programmatic implementation of grants, contracts and special initiatives associated with national discretionary activity. Provides management of ORR discretionary grants; computes grantee allocations, and monitors grantee expenditures; analyzes financial needs under discretionary grant programs; provides data in support of apportionment requests; and provides technical assistance on discretionary grants operations. The ORR coordinates and provides liaison with the Department and other federal agencies on discretionary grants operational issues and other activities as specified by the Director or required by Congressional mandate.

The Division ensures the quality of medical screening and initial medical treatment of refugees; collects data and performs analyses on the changing needs of the refugee and entrant population; provides leadership to identify data needs and sources, formulates data and reporting requirements; assists states and private agencies on data reporting and the resolution of reporting problems; compiles, evaluates, and disseminates information on the nationwide performance and costs of refugee service programs; responds to unanticipated refugee and entrant arrivals or significant increases in arrivals to communities where adequate or appropriate services do not exist; strengthens the role of ethnic community national or multi-State organizations to promote economic independence among refugees; provides for English Language Training and provides where specific needs have been shown and recognized by the Director for health (including mental health) services, social services, educational and other services.

The Division develops Repatriation plans to make arrangements and approve payments for temporary assistance to certain U.S. citizens and dependents repatriated from foreign countries, and for the hospitalization of certain U.S. Nationals repatriated because of mental illness.

Dated: August 3, 1998.

Olivia A. Golden,

Assistant Secretary for Children and Families.

[FR Doc. 98–21077 Filed 8–5–98; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0320]

Agency Emergency Processing Request Under OMB Review; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of June 11, 1998 (63 FR 32102). The document announced an opportunity for public comment on a proposed collection of information that has been submitted to the Office of Management and Budget for emergency processing under the Paperwork Reduction Act of 1995. The notice published with an error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In FR Doc. 98–15484, appearing on page 32102, in the **Federal Register** of Thursday, June 11, 1998, the following correction is made:

1. On page 32103, in the second column, beginning in the first line, ''a nutrient claim or a health claim that is based on an authoritative statement of a scientific body of the Federal Government or the National Academy of Sciences. Under these sections of the act, a food producer that intends to use such a claim must submit a notification of its intention to use the claim 120 days before it begins marketing'' is corrected to read ''a nutrient content claim or a health claim that is based on an authoritative statement of certain scientific bodies of the Federal Government or of the National Academy of Sciences or any of its subdivisions. Under these sections of the act, a food producer may use such a claim in the labeling of an appropriate product 120 days after a complete notification of the claim is submitted to FDA''.

Dated: July 29, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–20956 Filed 8–5–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Biotechnology Manufacturing Grassroots Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

SUMMARY: The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Pacific Region, and the Center for Biologics Evaluation and Research (CBER), is announcing the following meeting: Biotechnology Manufacturing Grassroots Meeting. The topic to be discussed is mechanisms and processes through which the agency could potentially increase operational efficiency in relation to both the pre- and post-approval inspection process; improve communication and cooperation among CBER, FDA field offices, and industry representatives associated with biotechnology manufacturing processes; and improve levels of consumer protection.

DATES: The meeting will be held on Tuesday, September 15, 1998, from 8:30 a.m. to 3:30 p.m.

ADDRESSES: The meeting will be held at the Los Angeles District Office, Food and Drug Administration, 19900 MacArthur Blvd., suite 300, Irvine, CA 92715.

FOR FURTHER INFORMATION CONTACT: Mark Roh (HFR–PA17), Pacific Regional Office, Food and Drug Administration, 1301 Clay St., suite 1180–N, Oakland, CA 94612, 510–637–3980, fax 510–637–3977, e-mail ''mroh@ora.fda.gov''.